Sanofi's Eczema Drug: Amlitelimab's Disappointing Trial Results

Sanofi's stock plunges as its potential Dupixent successor, amlitelimab, disappoints in late-stage trials. Is this the end of Sanofi's dominance in eczema treatment, or can the drug's convenient dosing save it? Find out why analysts are skeptical and what this means for the future of Sanofi. Hosted on Acast. See acast.com/privacy for more information.